Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generall...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/17/13454 |
| _version_ | 1797582421098496000 |
|---|---|
| author | Arnaud J. Legrand Souhaila Choul-li Vincent Villeret Marc Aumercier |
| author_facet | Arnaud J. Legrand Souhaila Choul-li Vincent Villeret Marc Aumercier |
| author_sort | Arnaud J. Legrand |
| collection | DOAJ |
| description | ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications. |
| first_indexed | 2024-03-10T23:21:58Z |
| format | Article |
| id | doaj.art-dfb63532edfc4967b3c99f11e6778258 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T23:21:58Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-dfb63532edfc4967b3c99f11e67782582023-11-19T08:17:32ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-08-0124171345410.3390/ijms241713454Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing TumoursArnaud J. Legrand0Souhaila Choul-li1Vincent Villeret2Marc Aumercier3CNRS, EMR9002 Integrative Structural Biology, F-59000 Lille, FranceDépartement de Biologie, Faculté des Sciences, Université Chouaib Doukkali, BP-20, El Jadida 24000, MoroccoCNRS, EMR9002 Integrative Structural Biology, F-59000 Lille, FranceCNRS, EMR9002 Integrative Structural Biology, F-59000 Lille, FranceETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications.https://www.mdpi.com/1422-0067/24/17/13454ETS transcription factorsPARP-1pharmacological inhibitioncancer therapyDNA damage |
| spellingShingle | Arnaud J. Legrand Souhaila Choul-li Vincent Villeret Marc Aumercier Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours International Journal of Molecular Sciences ETS transcription factors PARP-1 pharmacological inhibition cancer therapy DNA damage |
| title | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
| title_full | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
| title_fullStr | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
| title_full_unstemmed | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
| title_short | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
| title_sort | poly adp ribose polyremase 1 parp 1 inhibition a promising therapeutic strategy for ets expressing tumours |
| topic | ETS transcription factors PARP-1 pharmacological inhibition cancer therapy DNA damage |
| url | https://www.mdpi.com/1422-0067/24/17/13454 |
| work_keys_str_mv | AT arnaudjlegrand polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT souhailachoulli polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT vincentvilleret polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT marcaumercier polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours |